MichaelGSensionMD

PubMed

• 2 citations
  Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort.
  Michael G Sension, Laurence Brunet, Ricky K Hsu, Jennifer S Fusco, Quateka Cochran, Christine Uranaka, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Lewis McCurdy...> ;Infectious Diseases and Therapy. 2023 Dec 1
• 4 citations
  Immune response to ART initiation in advanced HIV infection.
  Karam Mounzer, Laurence Brunet, Jennifer S Fusco, Ian R McNicholl, Megan Dunbar, Michael Sension, Lewis H McCurdy, Gregory P Fusco> ;HIV Medicine. 2023 Jun 1
• 2 citations
  Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
  Steven K Barnett, Laura Armas-Kolostroubis, Michael Sension, David J Riedel> ;AIDS. 2022 Aug 1
• 12 citations
  Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens.
  Karam Mounzer, Laurence Brunet, Jennifer S Fusco, Ian R Mcnicholl, Helena Diaz Cuervo, Michael Sension, Lewis Mccurdy, Gregory P Fusco> ;Open Forum Infectious Diseases. 2022 Mar 1
• 13 citations
  Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
  Michael Sension, Henri Deckx> ;AIDS Reviews. 2015 Jan 1
• 52 citations
  Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1–Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE T...
  Pablo Tebas, Michael Sension, Jose R. Arribas, D. Duiculescu, Eric Florence, Chien-Ching Hung, Timothy J. Wilkin, Simon Vanveggel, Marita Stevens, Henri Deckx> ;Clinical Infectious Diseases. 2014 Aug 1
• Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associate...
  Sension, M.,Cahn, P.,Domingo, P.,Hodder, S.,Opsomer, M.,Lathouwers, E.,Van de Casteele, T.,Tomaka, F.> ;HIV Med.. 2013 Aug
• 3 citations
  Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir
  Richard Elion, Daniel S Berger, Gary Richmond, Michael Sension, Edwin DeJesus, Cimoch Pj, Marty St. Clair, Linda Yau, Belinda Ha> ;HIV Clinical Trials. 2010 May 1
• 20 citations
  Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine earl...
  William J. Towner, Jacob Lalezari, Michael Sension, Michael Wohlfeiler, Joseph Gathe, Jonathan S Appelbaum, Paul Bellman, Michael S. Gottlieb, Robert Ryan, Steven Nijs...> ;Journal of Acquired Immune Deficiency Syndromes. 2010 Feb 1
• 29 citations
  Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.
  Michael Sension, Jose Luiz de Andrade Neto, Beatriz Grinsztejn, Jean-Michel Molina, Isidro Zavala, Juan González-García, Alice Donnelly, Phillip Phiri, Emilio Ledesma,...> ;Journal of Acquired Immune Deficiency Syndromes. 2009 Jun 1
• 15 citations
  Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
  Charles B. Hicks, Edwin DeJesus, Louis Sloan, Michael Sension, David A. Wohl, Qiming Liao, Lisa L. Ross, Gary E Pakes, Keith A. Pappa, C. Tracey Lancaster> ;AIDS Research and Human Retroviruses. 2009 Apr 10
• 23 citations
  Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
  Richard Elion, Edwin DeJesus, Michael Sension, Daniel S Berger, William J. Towner, Gary Richmond, Marty St. Clair, Linda Yau, Belinda Ha> ;HIV Clinical Trials. 2008 May 1
• 10 citations
  Long-Term Suppression of HIV Infection: Benefits and Limitations of Current Treatment Options
  Michael G. Sension> ;The Journal of the Association of Nurses in AIDS Care. 2007 Jan 1
• 5 citations
  Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.
  Michael Sension, Peter J. Piliero> ;The Journal of the Association of Nurses in AIDS Care. 2007 Jan 1
• 30 citations
  Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplif...
  Philip Keiser, Michael Sension, Edwin DeJesus, Allan Rodriguez, Jeffrey F Olliffe, Vanessa C. Williams, John H Wakeford, Jerry W Snidow, Anne Shachoy-Clark, Julie W Fl...> ;BMC Infectious Diseases. 2005 Jan 12
• 251 citations
  Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
  Kathleen Squires, Adriano Lazzarin, Jose M. Gatell, William G. Powderly, Vadim Pokrovskiy, Jean François Delfraissy, Joseph G. Jemsek, Antonio Rivero, Willy Rozenbaum,...> ;Journal of Acquired Immune Deficiency Syndromes. 2004 Aug 15
• 50 citations
  Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomiz...
  Edwin DeJesus, Debra Mccarty, Charles Farthing, Denise D Shortino, Beatriz Grinsztejn, Deborah A. Thomas, Shannon Schrader, Steve A. Castillo, Michael Sension, Kevin G...> ;Clinical Infectious Diseases. 2004 Aug 1
• 83 citations
  Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
  Robin Wood, Praphan Phanuphak, Pedro Cahn, Vadim Pokrovskiy, Willy Rozenbaum, Giuseppe Pantaleo, Michael Sension, Robert L. Murphy, Marco Mancini, Thomas Kelleher, Mic...> ;Journal of Acquired Immune Deficiency Syndromes. 2004 Jun 1
• Initial therapy for human immunodeficiency virus: broadening the options.
  Michael Sension> ;HIV Clinical Trials. 2004 Mar 1
• 155 citations
  Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus—Infected Patients Switched from Stavudine to Abacavir o...
  Grace A. McComsey, Douglas J. Ward, Siegrid M. Hessenthaler, Michael Sension, Peter Shalit, J. Tyler Lonergan, Robin L. Fisher, Vanessa C. Williams, Jaime E. Hernandez> ;Clinical Infectious Diseases. 2004 Jan 15
• 9 citations
  Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.
  Michael Sension, Nicholaos C. Bellos, Judy Johnson, Gladys E. Sepulveda, Edwin DeJesus, Jorge Santana, Michael H. Ames, S. Diane Goodwin> ;HIV Clinical Trials. 2002 Sep 1
• 14 citations
  Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
  Harold A. Kessler, Judy Johnson, Stephen E. Follansbee, Michael Sension, Donna Mildvan, Gladys E. Sepulveda, Nicholaos C. Bellos, Seth Hetherington> ;Clinical Infectious Diseases. 2002 Feb 15
• 42 citations
  Vitamin A Levels and Mortality Among Hospitalized Measles Patients, Kinshasa, Zaire
  Lauri E. Markowitz, Nzila Nzilambi, W J Driskell, Michael G. Sension, Elizabeth Z. Rovira, Phillip Nieburg, Robert W. Ryder> ;Journal of Tropical Pediatrics. 1989 Jun 1
• 28 citations
  Measles in hospitalized African children with human immunodeficiency virus.
  Michael G. Sension, Thomas C. Quinn, Lauri E. Markowitz, Michael J. Linnan, T. Stephen Jones, Henry Francis, Nzila Nzilambi, Mvunza Npaka Duma, Robert W. Ryder> ;American Journal of Diseases of Children. 1988 Dec 1
• 30 citations
  Rapid latex agglutination assay using recombinant envelope polypeptide for the detection of antibody to the HIV.
  Thomas C. Quinn, Charles H. Riggin, Richard Kline, Henry L. Francis, Kabeya Mulanga, Michael G. Sension, Anthony S. Fauci> ;JAMA. 1988 Jul 22
• Join now to see all